Hovione Company Market Research Report

Company Overview

Name and Mission

Name: Hovione

Mission: Hovione is committed to nurturing a strong quality culture that leads to safe medicines, serving patients with uncompromising honesty, integrity, and transparency. The company is dedicated to helping pharmaceutical customers bring new and off-patent drugs to market by providing contract development and manufacturing services.

Founding and Key People

Founded: 1959

Founders: Ivan Villax with his wife, Diane Villax, alongside co-founders Nicholas de Horthy and Andrew Onody.

Key People:

Jean-Luc Herbeaux: Chief Executive Officer (CEO)

António Almeida: Chief Financial Officer (CFO)

Stefan Doboczky: Chairman of the Board

Ilda Ventura: Vice-President for Human Resources

Marco Gil: Senior Vice President - Sales & Marketing

Headquarters and Presence

Headquarters: Sete Casas, 2674-506 Loures, Portugal

Global Presence: Manufacturing plants in Loures (Portugal), Cork (Ireland), East Windsor (NJ, USA), and Macau. Offices and R&D centers in various locations, including Lisbon, Macau, New Jersey, and Japan.

Number of Employees

Approximately 2,300 employees worldwide

Revenue

No information is available

Recognitions

Top Employer 2024: Recognized as a Top Employer in all manufacturing sites, including Macau, Portugal, USA, and Ireland.

Known For

Leading expertise in spray drying and particle engineering, providing comprehensive services throughout the drug lifecycle.

Products and Services

Key Products and Technologies

Spray Drying:

High-level Description: A continuous process used primarily for overcoming solubility issues related to oral drugs, inhalable particles, specialty excipients, and thermally labile products isolation.

Key Features:

Production of solid dispersions

Microencapsulation for taste masking and delivery enhancement

Isolation of temperature-sensitive materials

Continuous Tableting:

High-level Description: A process that expedites the transition from development to manufacturing with high quality and fewer variabilities.

Dispersome® Technology:

Developed in partnership with Zerion Pharma to enhance solubility and bioavailability of small drug molecules.

PowdAir:

A 3-step inhalation device that is simple, effective, and economical.

Other Services

Contract Manufacturing Services

Development by Design for spray-dried products

Quality and compliance support services

Recent Developments

New Products and Features

Continuous Tableting Line: Recently inaugurated at Hovione's R&D Center in Lisbon, facilitating advanced manufacturing capabilities.

Dispersome® Technology Joint Venture: Collaboration with Zerion Pharma to expand this proprietary solubility enhancement technology's reach.

Partnerships and Collaborations

ViSync® Technologies: A joint venture with iBET focused on innovating solutions for cell and gene therapy.

GEA Partnership: Collaboration to advance continuous tableting technology.

Sustainability:

Committed to science-based targets for reducing greenhouse gas emissions in alignment with the Paris Agreement.

Recent Recognitions

Awarded in HR Achievements: Recognition at Deloitte's Investor Relations & Governance Awards (IRGAwards) 2024.

Recognition by Macau Government: Acknowledged for contributions with the Medal of Merit.

Strategic Contacts

Strategic Partners: Initiated a partnership with Higuchi to strengthen the presence in Japan.

Conclusion

Hovione, with over 60 years of experience, remains a key player in the pharmaceutical development and manufacturing sector, distinguished by its technological innovation and commitment to quality. With active engagements in sustainability initiatives and strategic global partnerships, the company is poised for continued impact and growth in the pharmaceutical industry.